Human islet amyloid polypeptide (hIAPP) - A curse in type II diabetes mellitus: Insights from structure and toxicity studies

Abstract

The human islet amyloid polypeptide (hiapp) or amylin, a neuroendocrine peptide hormone, is known to misfold and form amyloidogenic aggregates that have been observed in the pancreas of 90% subjects with type 2 diabetes mellitus (t2dm). Under normal physiological conditions, hiapp is co-stored and co-secreted with insulin; however, under chronic hyperglycemic conditions associated with t2dm, the overexpression of hiapp occurs that has been associated with the formation of amyloid deposits; as well as the death and dysfunction of pancreatic β-islets in t2dm. Hitherto, various biophysical and structural studies have shown that during this process of aggregation, the peptide conformation changes from random structure to helix, then to β-sheet, subsequently to cross β-sheets, which finally form left-handed helical aggregates. The intermediates, formed during this process, have been shown to induce higher cytotoxicity in the β-cells by inducing cell membrane disruption, endoplasmic reticulum stress, mitochondrial dysfunction, oxidative stress, islet inflammation, and dna damage. As a result, several research groups have attempted to target both hiapp aggregation phenomenon and the destabilization of preformed fibrils as a therapeutic intervention for t2dm management. In this review, we have summarized structural aspects of various forms of hiapp viz. Monomer, oligomers, proto-filaments, and fibrils of hiapp. Subsequently, cellular toxicity caused by toxic conformations of hiapp has been elaborated upon. Finally, the need for performing structural and toxicity studies in vivo to fill in the gap between the structural and cellular aspects has been discussed. © 2020 walter de gruyter gmbh, berlin/boston 2020.